NFA
STML

Nationwide Fund Advisors’s Stemline Therapeutics, Inc. STML Stock Holding History

Nationwide Fund Advisors’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-12,755
Closed -$142K – 2680
2017
Q3 		$142K Hold
12,755
– – ﹤0.01% 2770
2017
Q2 		$117K Buy
12,755
+855
+7% +$7.13K ﹤0.01% 2843
2017
Q1 		$102K Buy
11,900
+858
+8% +$7.82K ﹤0.01% 2837
2016
Q4 		$118K Hold
11,042
– – ﹤0.01% 2818
2016
Q3 		$120K Sell
11,042
-11,353
-51% -$92.3K ﹤0.01% 2830
2016
Q2 		$152K Buy
22,395
+8,670
+63% +$54.7K ﹤0.01% 2745
2016
Q1 		$93K Buy
13,725
+3,540
+35% +$17.3K ﹤0.01% 2853
2015
Q4 		$64K Hold
10,185
– – ﹤0.01% 2955
2015
Q3 		$90K Hold
10,185
– – ﹤0.01% 2925
2015
Q2 		$120K Sell
10,185
-21,789
-68% -$303K ﹤0.01% 2965
2015
Q1 		$463K Buy
31,974
+23,006
+257% +$352K ﹤0.01% 2277
2014
Q4 		$153K Hold
8,968
– – ﹤0.01% 2767
2014
Q3 		$112K Buy
8,968
+170
+2% +$2.09K ﹤0.01% 2944
2014
Q2 		$129K Buy
8,798
+1,331
+18% +$20.4K ﹤0.01% 2944
2014
Q1 		$152K Hold
7,467
– – ﹤0.01% 2606
2013
Q4 		$146K Buy
7,467
+170
+2% +$4.54K ﹤0.01% 2825
2013
Q3 		$330K Buy
7,297
+4,368
+149% +$142K ﹤0.01% 2428
2013
Q2 		$70K Buy
+2,929
New +$46.6K ﹤0.01% 2897

Other funds holding STML

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

Nationwide Fund Advisors's STML Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Stemline Therapeutics, Inc. (STML) in Q4 2017, closing a stake of 12,755 shares — an estimated $142K sold.

Nationwide Fund Advisors first reported a position in STML in Q2 2013 and held it in 18 quarters. The position peaked at $463K in Q1 2015. 80 funds tracked by Wall St. Rank hold STML as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Stemline Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 12,755 Stemline Therapeutics, Inc. shares in Q4 2017, an estimated $142K.
  • Nationwide Fund Advisors first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 18 quarters.
  • Nationwide Fund Advisors's Stemline Therapeutics, Inc. position peaked at $463K in Q1 2015.
  • 80 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.